# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
https://www.forbes.com/sites/roberthart/2024/07/08/zepbound-sheds-more-weight-than-wegovy-study-finds/Eli Lilly's popular o...
Eli Lilly to acquire Morphic Holding Inc for $3.2 billion, strengthening its portfolio in chronic disease treatments. Morphic...
Eli Lilly and Co. (NYSE: LLY) shares are experiencing increased activity Friday afternoon. Here's what you need to know.
A study finds that GLP-1 treatments, including Novo Nordisk's Ozempic and Eli Lilly's Mounjaro, significantly reduce th...
https://news.bloomberglaw.com/health-law-and-business/ozempic-may-lower-risk-of-obesity-related-cancers-study-finds